Diabetes causes 12 percent of deaths in the United States, making it the third-leading cause of death nationally behind cardiovascular disease and cancer. The death toll is higher than previously expected for the United States, which leads the world in spending on diabetes at $320 billion per year. The finding came to light through a study conducted by researchers at the University of Pennsylvania and Boston University and published in PLOS ONE.
The Centers for Disease Control has projected that 1 in 3 adult Americans will have diabetes by 2050. Adult diabetics have a 50% higher risk of premature death, primarily due to preventable complications like cardiovascular disease, which kills two-thirds of Americans with diabetes. With prevention efforts failing—obesity is the leading risk factor for developing diabetes, and less than 1% of obese people ever reach normal weight—much of the burden of reducing the diabetes death toll will depend on treatment.
Patients who start insulin immediately have lower rates of all diabetes-related complications, whereas patients on traditional monotherapy show a 14.25% decline in glycemic control every 3 years. So why aren’t more patients on insulin? In the US and other developed countries, the problem isn’t a shortage of insulin but a shortage of endocrinologists with time and training to make routine, well-reasoned dose adjustments. At Insulin Algorithms, we call this problem the endocrinology care gap. And we have a solution. Our desktop software makes it easy for clinicians of every level to analyze a patient’s glycemic data and optimally adjust their dosing regimen, using algorithms that are proven to lower HbA1c. Learn more